A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The treatment landscape for HIV is discussed by a panel led by Dr Welch. Adam C. Welch, PharmD, MBA: Let’s get into some of those treatments. Shauna, can you provide an overview of how we treat HIV?

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Assessing the quality of an HIV treatment plan is crucial to patient prognosis. Adam C. Welch, PharmD: When we talk about poor tolerability in patient treatment options and needing to switch to ...

For the first time in 19 years, a team of scientists has detected a new strain of HIV. The strain is a part of the Group M version of HIV-1, the same family of virus subtypes to blame for the global ...